E Andrew Townsend1, S Stevens Negus1, Justin L Poklis1, Matthew L Banks2. 1. Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA. 2. Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA. Electronic address: matthew.banks@vcuhealth.org.
Abstract
BACKGROUND: The current opioid crisis has reinvigorated preclinical research in the evaluation of non-opioid candidate treatments for opioid use disorder (OUD). Emerging evidence suggests 5-HT2C receptor agonists may attenuate the abuse-related effects of opioids. This study evaluated effectiveness of 7-day treatment with the clinically available 5-HT2C agonist lorcaserin (Belviq®) on heroin-vs.-food choice in rhesus monkeys. Lorcaserin effects were compared to effects produced by 7-day saline substitution and by 7-day treatment with the opioid antagonist naltrexone. METHODS: Adult male (1) and female (6) rhesus monkeys were trained to respond under a concurrent schedule of food delivery (1 g pellets, fixed-ratio 100 schedule) and intravenous heroin injections (0-0.032 mg/kg/injection, fixed-ratio 10 schedule) during daily 2 h sessions. Heroin choice dose-effect functions were determined daily before and following 7-day saline substitution or 7-day continuous treatment with naltrexone (0.0032-0.032 mg/kg/h, IV) or lorcaserin (0.032-0.32 mg/kg/h, IV). RESULTS: Under baseline conditions, increasing heroin doses maintained a dose-dependent increase in heroin choice. Both saline substitution and 7-day naltrexone treatment significantly attenuated heroin choice and produced a reciprocal increase in food choice. Continuous lorcaserin (0.32 mg/kg/h) treatment significantly increased heroin choice. CONCLUSIONS: In contrast to saline substitution and naltrexone, lorcaserin treatment was ineffective to reduce heroin-vs.-food choice. These preclinical results do not support the therapeutic potential and continued evaluation of lorcaserin as a candidate OUD treatment.
BACKGROUND: The current opioid crisis has reinvigorated preclinical research in the evaluation of non-opioid candidate treatments for opioid use disorder (OUD). Emerging evidence suggests 5-HT2C receptor agonists may attenuate the abuse-related effects of opioids. This study evaluated effectiveness of 7-day treatment with the clinically available 5-HT2C agonist lorcaserin (Belviq®) on heroin-vs.-food choice in rhesus monkeys. Lorcaserin effects were compared to effects produced by 7-day saline substitution and by 7-day treatment with the opioid antagonist naltrexone. METHODS: Adult male (1) and female (6) rhesus monkeys were trained to respond under a concurrent schedule of food delivery (1 g pellets, fixed-ratio 100 schedule) and intravenous heroin injections (0-0.032 mg/kg/injection, fixed-ratio 10 schedule) during daily 2 h sessions. Heroin choice dose-effect functions were determined daily before and following 7-day saline substitution or 7-day continuous treatment with naltrexone (0.0032-0.032 mg/kg/h, IV) or lorcaserin (0.032-0.32 mg/kg/h, IV). RESULTS: Under baseline conditions, increasing heroin doses maintained a dose-dependent increase in heroin choice. Both saline substitution and 7-day naltrexone treatment significantly attenuated heroin choice and produced a reciprocal increase in food choice. Continuous lorcaserin (0.32 mg/kg/h) treatment significantly increased heroin choice. CONCLUSIONS: In contrast to saline substitution and naltrexone, lorcaserin treatment was ineffective to reduce heroin-vs.-food choice. These preclinical results do not support the therapeutic potential and continued evaluation of lorcaserin as a candidate OUD treatment.
Authors: Joi L Dunbar; Ryan Z Turncliff; Qunming Dong; Bernard L Silverman; Elliot W Ehrich; Kenneth C Lasseter Journal: Alcohol Clin Exp Res Date: 2006-03 Impact factor: 3.455
Authors: Joshua D Lee; Edward V Nunes; Patricia Novo; Ken Bachrach; Genie L Bailey; Snehal Bhatt; Sarah Farkas; Marc Fishman; Phoebe Gauthier; Candace C Hodgkins; Jacquie King; Robert Lindblad; David Liu; Abigail G Matthews; Jeanine May; K Michelle Peavy; Stephen Ross; Dagmar Salazar; Paul Schkolnik; Dikla Shmueli-Blumberg; Don Stablein; Geetha Subramaniam; John Rotrosen Journal: Lancet Date: 2017-11-14 Impact factor: 79.321
Authors: Matthew L Banks; Blake A Hutsell; Bruce E Blough; Justin L Poklis; S Stevens Negus Journal: Int J Neuropsychopharmacol Date: 2015-01-24 Impact factor: 5.176
Authors: Laura Brandt; Jermaine D Jones; Suky Martinez; Jeanne M Manubay; Shanthi Mogali; Tatiana Ramey; Frances R Levin; Sandra D Comer Journal: Drug Alcohol Depend Date: 2020-01-17 Impact factor: 4.492
Authors: E Andrew Townsend; Paul T Bremer; Kaycee E Faunce; S Stevens Negus; Alaina M Jaster; Hannah L Robinson; Kim D Janda; Matthew L Banks Journal: ACS Chem Neurosci Date: 2020-04-22 Impact factor: 4.418
Authors: E Andrew Townsend; Bruce E Blough; David H Epstein; S Stevens Negus; Yavin Shaham; Matthew L Banks Journal: Neuropsychopharmacology Date: 2022-07-29 Impact factor: 8.294
Authors: Frances R Levin; John J Mariani; Martina Pavlicova; C Jean Choi; Cale Basaraba; Amy L Mahony; Daniel J Brooks; Nasir Naqvi; Adam Bisaga Journal: Drug Alcohol Depend Date: 2021-01-05 Impact factor: 4.492
Authors: E Andrew Townsend; Kathryn L Schwienteck; Hannah L Robinson; Stephen T Lawson; Matthew L Banks Journal: J Neurosci Methods Date: 2021-03-08 Impact factor: 2.390
Authors: E Andrew Townsend; Paul T Bremer; Nicholas T Jacob; S Stevens Negus; Kim D Janda; Matthew L Banks Journal: Drug Alcohol Depend Date: 2020-10-20 Impact factor: 4.492